药物研发领域人工智能应用与创新发展策略探讨  

Discussion on application and innovative development strategy of artificial intelligence in drug research and development field

作　　者：茅鸯对[1] 柳鹏程[2] MAO Yang-dui;LIU Peng-cheng(School of Business,Zhejiang Pharmaceutical College,Ningbo ZHEJIANG 315000,China;School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing JIANGSU 211198,China)

机构地区：[1]浙江医药高等专科学校商学院,浙江宁波315000 [2]中国药科大学国际医药商学院,江苏南京211198

出　　处：《中国新药与临床杂志》2021年第6期430-435,共6页Chinese Journal of New Drugs and Clinical Remedies

基　　金：浙江省哲学社会科学规划课题(19NDJC404YBM);浙江省药品监管系统科技计划项目(2021032);浙江省教育厅访问工程师校企合作项目(FG2019006)。

摘　　要：人工智能是药物研发的强大加速器,在降低研发成本的同时能大幅缩短新药上市周期。目前自然语言处理、机器学习、深度学习、知识图谱等人工智能关键技术在药物靶点发现、活性化合物筛选、分子生成等新药研发环节已得到广泛应用,全球多家人工智能企业与制药企业已开启深度合作模式。但人工智能在药物研发领域的应用仍存在人工智能监管法规缺位、制药企业技术创新效率未达预期以及研发各方未形成有效合力的困境,施行监管与非监管并行措施、合理选择药物研发路径、搭建政产学研用协同生态系统等措施有助于我国医药产业高质量发展。Artificial intelligence is a powerful accelerator of drug research and development, which can significantly shorten the time to market while reducing costs. At present, the key artificial intelligence technologies such as natural language processing, machine learning, deep learning and knowledge graph have been widely used in new drug research and development processes including drug target discovery, active compound screening, molecular generation and so on. A number of artificial intelligence enterprises around the world have started deep cooperation mode with pharmaceutical enterprises. However, the difficulties in the application of artificial intelligence in the field of new drug research and development mainly include the absence of artificial intelligence regulatory regulations, the failure to meet the expectation of pharmaceutical enterprises’ technology innovation efficiency and the lack of effective synergy from research and development parties. Measures including implementation of regulatory and non-regulatory parallel measures, rational choice of drug innovation path, building a collaborative ecosystem of government-industry-universityresearch-user, etc. contribute to high-quality development of my country’s pharmaceutical industry.

关 键 词：人工智能 药物设计 跨学科配置 制药工业 政府政策 

分 类 号：R914.2[医药卫生—药物化学]